JPRN-C000000356已完成1 期
Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia - HSCT for aplastic anemia using alemtuzumab
GCP-ISS HE0403 group0 个研究点目标入组 38 人开始时间: 2006年3月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Diabetes uncontrollable even with regular insulin use. (2)Uncontrollable hypertension. (3)Current active infection. (4)5% or more malignant cell involvement in bone marrow. (5)Abnormality in chromosome 7 detected by bone marrow G-banding or FISH. (6)Current active cancer. (7)Pregnant or nursing women or women who may be pregnant. (8)Uncontrollable mental illness. (9)Hepatitis B virus antigen-positive (HBsAg or HBeAg). (10)HIV-positive. (11)A history of hypersensitivity to transplant conditioning agents (fludarabine phosphate, cyclophosphamide) or agents for GVHD prophylaxis (ciclosporin, methotrexate). (12)A history of hematopoietic stem cell transplantation.
研究者
相似试验
招募中
1 期
Evaluation of the safety and efficacy of allogeneic activated Natural killer cells in metastatic Colon AdenocarcinomaIRCT20230704058675N1Middle East Gene Therapy corporation10
尚未招募
1 期
Assessment of the effect of allogeneic adipose derived mesenchymal stem cells along with platelet rich fibrin for perianal fistulas in treatment of perianal fistulasperianal fistula.Fistula, other specified siteM25.18IRCT20210830052332N1Iranian academic center for education culture and research24
已完成
1 期
Evaluation of the safety and efficacy of allogenic hematopoietic stem cell transplantation (HSCT) from HLA-mismatched related donors using alemtuzumab in patients with hematological malignancies.Hematological malignanciesJPRN-C000000357GCP-ISS HE0402 group48
招募中
不适用
Safety and efficacy of Mesenchymal Stem Cell administration in Bronchiolitis Obliterans Syndrome.IRCT20201202049568N2Tehran University of Medical Sciences10
招募中
1 期
Effect of NK cell therapy in COVID-19IRCT20200417047113N1Middle East Gene Therapy corporation70